Principal Scientist at the Cardiovascular Research Centre, Bayer AG, Wuppertal, Germany
Stefan Heitmeier has worked for 20 years as a research scientist at Bayer AG, mostly in Wuppertal, Germany.
Dr. Heitmeier has a long-standing interest in the identification of targets for new antithrombotic approaches and drug candidate optimization and profiling and has presented his work at cardiology and thrombosis congresses.
Dr. Heitmeier graduated with a degree in Pharmacy from the Institute for Pharmaceutical Sciences, University of Muenster in Germany and gained his PhD degree in the field of bioanalysis of metabolic patterns of drugs in body fluids. He started his work at Bayer in the research centre in West Haven, Connecticut, in target discovery with novel receptor deorphaning strategies. In 2001, Dr. Heitmeier joined the lead structure identification group to develop assays for ultra-High Throughput Screening. From 2005 on, he has led a laboratory group conducting all kinds of in vitro and in vivo studies in thrombosis and vascular biology. In addition, Dr. Heitmeier has directed several multifunctional projects focusing on the identification, optimization and characterization of antithrombotic drugs, supports programs for novel antithrombotics in clinical development, and is involved in the ongoing characterization of the in vitro and in vivo pharmacological profile of the launched drug rivaroxaban.